GEN Exclusives

More »

GEN News Highlights

More »
May 7, 2009

Vernalis and Servier Sign Second Cancer Drug Discovery Agreement

  • Vernalis and Servier signed a three-year collaboration to harness Vernalis’ fragment- and structure-based drug discovery platform for the identification of drug candidates against a new cancer target.

    The deal is in addition to the companies’ existing collaboration, signed in May 2007, focused on two oncology targets involved in protein-protein interactions. In October 2008, Vernalis received a €500,000 milestone from Servier for solving the novel crystal structure of one of the targets.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Using CRISPRs to Tame GMOs

With more climate-induced droughts and insect infestations on the horizon do you think technologies like CRISPR will change a lot of people’s minds about GMOs, including genetically engineered foods?

More »